Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- Improving Healthcare Outcomes through IT Policy
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
Shows & Panels
Pfizer to pay $55 million in drug misbranding case
Wednesday - 12/12/2012, 3:40pm EST
WASHINGTON (AP) - The Justice Department says Pfizer Inc. will pay $55 million to resolve allegations that its subsidiary Wyeth LLC promoted the drug Protonix for uses that were not approved by the Food and Drug Administration.
In a written statement from its New York office, Pfizer, which acquired Wyeth in October 2009 years after the alleged misconduct, said that Pfizer was not a target or a subject of the case.
Wyeth obtained FDA approval to promote Protonix only for short-term treatment of erosive esophagitis. The condition is associated with gastro-esophageal reflux disease. Wyeth allegedly promoted Protonix for all forms of GERD from February 2000 to June 2001.
GERD is a condition in which food or liquid leak backwards from the stomach into the esophagus.
Pfizer's statement specifically denied allegations of wrongdoing.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)